Experimental CAR-T therapy for myeloma shows promise but trial halted
NCT ID NCT04318327
First seen Apr 04, 2026 · Last updated May 25, 2026 · Updated 9 times
Summary
This early-phase study tested a new type of immunotherapy called CAR-T cells that target a protein called BCMA on myeloma cells. The treatment involved taking a patient's own immune cells, engineering them to attack the cancer, and giving them back. The study aimed to check safety and see if the cells could shrink tumors in adults with multiple myeloma that had not responded to other treatments. The trial was terminated early, but the results help researchers understand how to improve this approach.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Cente
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Novartis Investigative Site
Melbourne, Victoria, 3004, Australia
-
Novartis Investigative Site
Ramat Gan, 5265601, Israel
-
Novartis Investigative Site
Tel Aviv, 6423906, Israel
-
Novartis Investigative Site
Singapore, 119074, Singapore
-
Novartis Investigative Site
Singapore, 169608, Singapore
-
Uni of Chi Medi Ctr Hema and Onco
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.